Coen Maas

Scientist

The Randstad, Netherlands

About

There is no solution without understanding the problem. I strive to combine fundamental science (understanding) with innovation (solution). Two things I enjoy in research: • Experimental questioning of an idea • Growth for my team members • 108 accepted publications, 42 last authorships (6000 citations; H-index 42; RCR 2) • Principal supervisor of 5 completed doctoral theses; 3 ongoing (IUS Promovendi since 2021) • 60+ Invited presentations • 2 patents (1 pending) • Co-founder of 2 spinout companies • Proud winner of the 2021 NVTH quiz (eternal glory)

Experience

  • UMC Utrecht (13 yrs 10 mos)
    • Associate Professor
      Jan 2018 - Feb 2025 · 7 yrs 2 mos

      • Principal investigator Coagulation & Fibrinolysis @ UMC Utrecht • Founder of TargED- Therapy and Diagnostics for microvascular thrombosis • Founder of SERPINx BV - Multitarget anti-inflammatory agents (IP sold) • 2020-onward Board Member NTVH: Dutch Society on Thrombosis and Hemostasis • 2019-present ISTH: Chair of SSC Committee Factor XI and the Contact System (co-chair 2017-19) • 2020 ISTH: Scientific Theme Leader Coagulation and Natural Anticoagulants. • 2021, 2022, 2023 ISTH: International Advisory Board • 2018-present Editorial Board: Seminars in Thrombosis and Haemostasis • 2016-present Editorial Board: Journal of Thrombosis and Haemostasis • 2016-present Review Editor: Frontiers in Medicine - Hematology • Licensed for academic teaching (BKO) - Course Coordinator Circulatory Health; Vasculature and Circulation

    • Assistant Professor
      May 2011 - Jan 2018 · 6 yrs 9 mos

      Interests: • The contact system and plasminogen activation • Angioedema & Kinin-related inflammatory conditions • Autoimmune microangiopathy • Thrombosis & Bleeding disorders With the help of talented PhD students, postdocs, guest researchers and undergraduate students, we are trying to understand how the contact system contributes to coagulation and inflammation. Hereto, we are building new bioassays to determine the activation of the involved factors in patient materials and perform mutagenesis studies to decipher pathological mechanisms. Furthermore, we are addressing the role of urokinase-driven plasminogen activation during vascular occlusions, with the aim of offering a new therapy for TTP. In satellite projects, we are studying the mechanisms by which megakaryocytes, the stem cells of blood platelets, take up Factor V and other proteins from the blood stream and are investigating endocannabinoid receptor signaling in platelets. In brief, we are having fun.

  • Adjunct Professor at Syddansk Universitet - University of Southern Denmark
    Sep 2020 - Dec 2024 · 4 yrs 4 mos

  • TargED Biopharmaceuticals (Utrecht, Netherlands)
    • Advisor
      Mar 2022 - Feb 2023 · 1 yr

    • Chief Scientific Officer
      Oct 2020 - Mar 2022 · 1 yr 6 mos

  • Postdoc at Karolinska Institutet
    Mar 2010 - Mar 2011 · 1 yr 1 mo

    Center for Molecular Medicine and Surgery Group of Prof. Thomas Renné Studying the kallikrein-kinin system in vivo.

  • Utrecht University Medical Center (5 yrs 2 mos)
    • Postdoc
      Jan 2009 - Feb 2010 · 1 yr 2 mos

      I am currently working on the biochemistry of the intrinsic pathway of blood coagulation. This mechanism has two sides: it is involved in the clotting of blood, but at the same time, it governs a potent inflammatory system. I am interested in the separation and overlap of these two routes in health and disease.

    • PhD. Student
      Jan 2005 - Jan 2009 · 4 yrs 1 mo

      I did my promotion here! Enjoyed it very much and learned a lot about science, the business of science, people and myself.